Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.

In the multicenter, open-label, single-arm MOLTO study (ClinicalTrials.gov Identifier: NCT04082897), researchers treated 28 patients with previously-untreated DLBCL-RT with atezolizumab plus ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...

Although the full results won't be presented at the upcoming ACR conference, a post hoc analysis of the obinutuzumab phase 2 data will be shared. Attendees can also look forward to the unveiling ...